KRIYA THERAPEUTICS

View On IC.GC.CA

CANCELLED

Last Applicant/ Owned by

KRIYA THERAPEUTICS INC.

1100 Island Drive, Suite 203Redwood City CA 94065

Serial Number

2066879 filed on 15^th Sept 2020

Registration Number

TMA1172247 registered on 22^nd Mar 2023

Registration expiry Date

15^th Sept 2030

Correspondent Address

SMART & BIGGAR LP

1000 RUE DE LA GAUCHETIERE OUESTBUREAU 3300MONTREAL

QUÉBEC

H3B4W5

KRIYA THERAPEUTICS

Trademark usage description

pharmaceutical preparations for use in gene therapy for the treatment of rare diseases, namely glycogen storage disease, lysosomal storage disorders, Read More

Vienna Information

1 . 13 . 1

Armillary spheres, planetaria, astronomic orbits, atomic models, molecular modelsSphères armillaires, planétariums, orbites astronomiques, schémas d'atomes, schémas de molécules

1 . 13 . 15

Atomic models, molecular models, representations of human, animal or vegetal cellsSchémas atomiques, schémas de molécules, représentations de cellules humaines, animales ou végétales

27 . 3 . 1

Letters or numerals representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an objectLettres ou chiffres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet

27 . 3 . 12

Letters or numerals representing a heavenly body or a natural phenomenonLettres ou chiffres représentant un corps céleste ou un phénomène naturel

Classification Information

Class [005]
Pharmaceutical preparations for use in gene therapy for the treatment of rare diseases, namely glycogen storage disease, lysosomal storage disorders, mitochondrial disorders, fatty acid oxidation disorders; Pharmaceutical preparations for use in gene therapy for the treatment of chronic diseases, namely, diabetes, gout, arthritis, anemia, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, growth and thyroid disorders, neuromuscular diseases, namely primary periodic paralysis, glucagonoma; Pharmaceutical preparations for use in gene therapy for the treatment of ophthalmic diseases namely macular degeneration, diabetic eye disease, Retinitis pigmentosa, retinal dystrophy, dry eye disease, corneal neovascularizarization, Graves' disease, Thyroid eye disease, diabetic macular edema, diabetic retinopathy, glaucoma, uveitis, retinopathy, blue cone monochromacy, achromatopsia, Usher syndrome, Stargardt disease, cone-rod dystrophy, Leber congenital amaurosis, Leber hereditary optic neuropathy, choroideremia, Bardet-Biedl syndrome, ocular channelopathies; Pharmaceutical preparations for use in gene therapy for the treatment of oncological diseases; Pharmaceutical preparations for use in gene therapy for the treatment of lymphangiogenesic diseases; Pharmaceutical preparations for use in gene therapy for the treatment of musculoskeletal diseases, cardiovascular diseases, cardiopulmonary diseases, urological diseases, hepatological diseases, respiratory diseases, viral diseases, central and peripheral nervous system diseases, trigeminal neuralgia, chronic pain, epilepsy, Parkinson's disease, addiction, schizophrenia, depression, tauopathies, Alzheimer's disease; Pharmaceutical preparations for use in gene therapy for the treatment of diseases of the complement system, inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, inflammatory muscle diseases, and neuroinflammatory diseases, gastrointestinal diseases, hormonal diseases, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata related diseases and disorders, auto-immune diseases, and heritable energy deficiency disorders leading to sudden death

Classification kind code

Class [042]
Testing, inspection, research, and development of pharmaceutical preparations for gene therapy; medical and scientific research in the field of gene therapy.

Classification kind code

Mark Details

Serial Number

2066879

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 15^th Mar 2022	Search Recorded
Submitted for opposition 20 on 15^th Mar 2022	Examiner's First Report
Submitted for opposition 256 on 27^th Sept 2021	Notification of Possible Opposition Sent
Submitted for opposition 48 on 15^th Mar 2021	Agent Changed
Submitted for opposition 135 on 20^th Jan 2021	Amendment to Application
Submitted for opposition 31 on 30^th Nov 2020	Formalized
Submitted for opposition 1 on 30^th Nov 2020	Created
Submitted for opposition 257 on 26^th Nov 2020	Designation Notification - Madrid Protocol
Submitted for opposition 228 on 15^th Sept 2020	International Registration
Submitted for opposition 30 on 15^th Sept 2020	Filed

KRIYA THERAPEUTICS

Classification Information

Classification kind code

Class [042]Testing, inspection, research, and development of pharmaceutical preparations for gene therapy; medical and scientific research in the field of gene therapy.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [042]
Testing, inspection, research, and development of pharmaceutical preparations for gene therapy; medical and scientific research in the field of gene therapy.